Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Renerve Limited ( (AU:RNV) ) has provided an announcement.
ReNerve Limited reported a 25.1% increase in its loss from ordinary activities after tax, amounting to $3,733,918 for the year ended 30 June 2025. Despite the financial setback, the company’s net tangible assets per ordinary security improved to 3.63 cents from a negative 0.19 cents in the previous period, indicating a positive shift in asset valuation.
More about Renerve Limited
ReNerve Limited operates in the biotechnology industry, focusing on the development of innovative medical solutions. The company is engaged in creating products that aim to improve nerve repair and regeneration, targeting a niche market within the medical field.
Average Trading Volume: 87,852
Technical Sentiment Signal: Strong Sell
Find detailed analytics on RNV stock on TipRanks’ Stock Analysis page.